Breast Cancer Awareness Month: Honoring Navigation

Best Practices in Breast Cancer – October 2017 Vol 8
Lillie D. Shockney, RN, BS, MAS, ONN-CG
Editor-in-Chief, JONS; Program Director, AONN+; University Distinguished Service Professor of Breast Cancer, Administrative Director, The Johns Hopkins Breast Center; Director, Johns Hopkins Cancer Survivorship Programs; Professor of Surgery and Oncology, JHU School of Medicine; Co-Creator, Work Stride-Managing Cancer at Work
shockli@jhmi.edu

Dear Navigators,

As you know, navigation as a profession began in breast cancer with the work of Harold P. Freeman, MD. Dr Freeman worked to identify and remove barriers to care for a community of women in need of breast cancer screening. The idea of “navigating” patients around those barriers in hope of impacting and improving patient outcomes resonated with the oncology community, and the term “patient navigation” was born.

To honor our connection to the field of breast cancer, we dedicate a special annual edition of the Journal of Oncology Navigation & Survivorship (JONS) to breast cancer and the strides being made in the treatment of this disease as part of our Best Practices series. Whereas JONS addresses navigation and oncology topics at large, we designed the Best Practices series to provide disease-specific education as well as exploring implications for navigators.

In this issue, we hear from Sharon S. Gentry, RN, MSN, AOCN, CBCN, ONN-CG, who provides a thorough overview of breast cancer treatment. We delve into a more sensitive consideration associated with cancer treatment – reproductive issues – in an informative article by Catherine Klein, MBA, BSN, RN, CBCN, OCN, ONN-CG, entitled “Addressing Fertility Concerns for Young Women with Breast Cancer.” On the forefront of innovations in side effect management are scalp cooling devices that can prevent hair loss associated with chemotherapy. You’ll read about these devices in an article from our Multinational Association of Supportive Care in Cancer coverage entitled “New Devices Prevent Chemotherapy-Induced Hair Loss.” 

The navigator’s role in the implementation of new devices is illustrated in our article entitled “The Many Faces of Nurse Navigators Delivering Cancer Care from Diagnosis to Treatment: Now Another Crucial Role to Play.”

We hope this issue enhances your practice and ultimately helps you to empower your patients living with breast cancer.

Sincerely,

Lillie D. Shockney, RN, BS, MAS, ONN-CG
Editor-in-Chief, JONS; Program Director, AONN+
University Distinguished Service Professor of Breast Cancer; Administrative Director, the Johns Hopkins Breast Center; Director, Cancer Survivorship Programs at the Sidney Kimmel Cancer Center at Johns Hopkins; Professor, JHU School of Medicine, Depts of Surgery and Oncology; Cofounder, Johns Hopkins Medicine Managing Cancer at Work.
E-mail: This email address is being protected from spambots. You need JavaScript enabled to view it.

Related Articles
FDA Expands Indication for Kadcyla to Include the Adjuvant Treatment of HER2-Positive Early Breast Cancer
Web Exclusives
On May 3, 2019, the US Food and Drug Administration (FDA) approved ado-trastuzumab emtansine (Kadcyla; Genentech) for the adjuvant treatment of patients with HER2-positive early breast cancer who have residual invasive disease after neoadjuvant taxane and trastuzumab-based treatment. Patients should be selected for treatment with this agent based on an FDA-approved companion diagnostic test (Ventana Medical System’s PATHWAY anti-HER-2/neu [4B5] Rabbit Monoclonal Primary Antibody assay or INFORM HER2 Dual ISH DNA Probe Cocktail assay).
Updated NCCN Breast Cancer Treatment Guideline Reflects Expanding Treatment Options for HR-Positive, HER2-Negative Disease
May 2019 Vol 10, No 5
T-DM1 Reduces Residual Invasive Disease in Patients with HER2-Positive Breast Cancer After Chemotherapy
May 2019 Vol 10, No 5
Last modified: June 9, 2018

Subscribe to the Journal of Oncology Navigation & Survivorship®

To sign up for our print publication or e-newsletter, please enter your contact information below.

  • First Name *
    Last Name *
     
    Country
  • Please enter your mailing address.

    Address
     
    Address Line 2
    City
     
    State
    Zip Code